Argenx (ARGX) said Wednesday it will proceed with developing its experimental drug, efgartigimod subcutaneous, to treat idiopathic inflammatory myopathies in its ongoing phase 2/3 study.
The decision follows data from phase 2 results that showed a significant treatment effect in the total improvement score at Week 24 and improvements across key measures in patients treated with efgartigimod subcutaneous compared to placebo.
The company said it will continue to enroll patients across each of the three myositis subtypes in the study, including immune-mediated necrotizing myopathy, anti-synthetase syndrome, and dermatomyositis.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments